Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol(DBM)-resistant Yoshida S.C. sarcoma.

× No keyword cloud information.

5 in total

1. [STUDIES ON THE RELATIONSHIP BETWEEN ALPHA-OMEGA SUBSTITUTION AND CYTOSTATIC ACTION OF SOME SUGAR ALCOHOL DERIVATIVES AND OF 1,6-DIBROMO-1,6-DIDESOXY-D-MANNITOL].

Authors: L INSTITORIS; P I HORVATH
Journal: Arzneimittelforschung Date: 1964-06

2. [THE EFFECT OF A NEW CYTOSTATIC, 1,6-DIBROMO-1,6-D-DIDESOXYMANNITOL, ON HEMATOPOIESIS IN RATS].

Authors: E CSANYI
Journal: Arzneimittelforschung Date: 1965-03

3. [Trial treatment of neoplastic diseases by 1,6-dibromomannitol].

Authors: C SELLEI; S ECKHARDT
Journal: Rev Fr Etud Clin Biol Date: 1963-05

4. Hematological effects of the alkylating agents.

Authors: L A ELSON
Journal: Ann N Y Acad Sci Date: 1958-04-24 Impact factor: 5.691

5. [EFFECT OF 1,6-DIBROMO-1,6-D-DIDESOXYMANNITOL (DBM) ON CHRONIC MYELOID LEUKEMIA].

Authors: S ECKHARDT; C SELLEI; P HORVATH; L INSTITORISZ; A MEDGYES; F MASSZI; F HARTAI; I HINDY
Journal: Orv Hetil Date: 1964-03-22 Impact factor: 0.540

5 in total

3 in total

Review 1. New drugs under clinical evaluation in the United States.

Authors: S K Carter
Journal: Cancer Chemother Pharmacol Date: 1978 Impact factor: 3.333

2. Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.

Authors: D A Amato; H Bruckner; D Guerry; A Ash; G Falkson; E C Borden; R H Creech; E D Savlov; T J Cunningham
Journal: Invest New Drugs Date: 1987 Impact factor: 3.850

3. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.

Authors: E Institóris; K Szikla; L Otvös; F Gál
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

3 in total